trial
as of 2026-07-01The Effects of Bimodal tDCS on Illness Severity, Insight, Functional Outcomes, Neurocognition and HRV in Schizophrenia
NCTId NCT03701100
at a glance
— · Completed
Enrollment 60 (actual)
Sponsored by Tri-Service General Hospital (TSGH)
Primary completion 2018-09-21
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-07-17
Primary completion
2018-09-21
Eligibility
ALL · 20 Years · 65 Years
Interventions & indications
Sponsors
Tri-Service General Hospital (TSGH)Lead Sponsor
Investigators
1
Hsin-An Chang, M.D.Principal Investigator
Sites
1 total
Taipei, Taiwan
Facts & assertions
4 sourced
Enrollment
60
Phase
NA
Primary Completion Date
2018-09-21
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person